XML 37 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Loss and Other Comprehensive Income - GBP (£)
£ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Consolidated Statements of Loss and Other Comprehensive Income [Abstract]      
Revenue £ 30,114 £ 25,669 £ 23,654
Total Revenue 30,114 25,669 23,654
Net other operating income 4,242 185 622
Research and development costs (74,809) (99,991) (83,575)
Administrative expenses (45,740) (44,183) (34,156)
Operating loss (86,193) (118,320) (93,455)
Other income 0 0 4,979
Finance income 2,208 1,510 1,140
Finance costs (3,375) (9,379) (842)
Non-operating (expense) / income (1,167) (7,869) 5,277
Loss before taxation (87,360) (126,189) (88,178)
Income tax credit 13,267 22,258 16,548
Loss for the year (74,093) (103,931) (71,630)
Other comprehensive (expense) / income that are or may be reclassified to profit or loss in subsequent periods (net of tax):      
Exchange differences on translation of foreign operations 195 (99) 72
Income tax effect relating to the components of other comprehensive income 0 0 3,634
Total other comprehensive (expense) / income for the year, net of tax 195 (99) 3,706
Total comprehensive loss for the year, net of tax £ (73,898) £ (104,030) £ (67,924)
Basic and diluted loss per share (in pounds per share) [1] £ (2.79) £ (4.66) £ (3.32)
[1] (1) The basic and diluted loss per share are adjusted for the (i) the exchange of shares of Immunocore Limited for shares of Immunocore Holdings Limited on a 1 for 100 basis, and (ii) the reorganization of the share capital of Immunocore Holdings plc, resulting in a consolidation with the effect of a 20 to 1 reverse stock split on the Company's ordinary shares and non-voting ordinary shares, all of which took place in connection with the Company's initial public offering which closed on February 9, 2021. No other adjustments have been made to the consolidated financial statements of the Group in regard to the corporate reorganization. Refer to Note 30 for further information.